Home   >  
Cell Cycle/DNA Damage
  • Epigenetics

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Tinengotinib Chemical Structure
BCP49223 Tinengotinib 2230490-29-4
Tinengotinib is an antineoplastic tyrosine kinase inhibitor.Tinengotinib is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase.
Aurora Kinase Inhibitor II Chemical Structure
BCP48936 Aurora Kinase Inhibitor II 331770-21-9
Aurora Kinase Inhibitor II is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively.
SP-146 Chemical Structure
BCP48903 SP-146 2682114-54-9
SP-146 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM. SP-146 can be used for the research of triple negative breast cancer (TNBC).
Aurora B inhibitor 1 Chemical Structure
BCP42843 Aurora B inhibitor 1 937276-52-3
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
SP-146 Chemical Structure
BCP35921 SP-146 SP-146
SP-146 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM.
Phthalazinone pyrazole Chemical Structure
BCP33311 Phthalazinone pyrazole 880487-62-7
Phthalazinone pyrazole is a potent, selective and orally bioavailable inhibitor of Aurora-A kinase.
 Chemical Structure
Aurora Kinase Inhibitor III Chemical Structure
BCP30248 Aurora Kinase Inhibitor III 879127-16-9
Aurora kinase inhibitor III is a potent inhibitor of Aurora A kinase (IC50 = 42 nM).
Cenisertib Chemical Structure
BCP28083 Cenisertib 871357-89-0
Cenisertib selectively binds to and inhibits aurora kinases (AKs), a family of serine-threonine kinases which are important regulators of cell division and proliferation, and which are overexpressed in certain types of cancer.
CCT241736 Chemical Structure
BCP29563 CCT241736 1402709-93-6
CCT241736 is a novel, orally bioavailable, imidazo[4,5-b]pyridine derivative discovered at our Institute, highly selective for FLT3 and Aurora kinases with an S(10) selectivity score using KINOMEscan™ technology of 0.057 (fraction of 386 non-mutant kinases inhibited >90% when screened at 1 uM of CCT241736; San Diego, CA).
123下一页末页共 44 条记录 1 / 5 页